Untitled Document
|
|
|
|
|
|
|
|
¡á ½ÄÇ°ÀǾàÇ°¾ÈÀüó ¼Ò½Ä |
|
¸Å´º¾ó/Áöħ |
¡¸3D ¹ÙÀÌ¿ÀÇÁ¸°Æà Á¦Ç° µî ¼¼Æ÷-ÁöÁöü º¹ÇÕÁ¦Ç°ÀÇ Æò°¡ °¡À̵å¶óÀΡ¹ ¹×
¡¸À¯ÀüÀÚÄ¡·áÁ¦ ºñÀÓ»ó½ÃÇè Æò°¡ °¡À̵å¶óÀΡ¹ ¹ß°£ |
|
½ÄÇ°ÀǾàÇ°¾ÈÀüó(óÀå ·ù¿µÁø) ½ÄÇ°ÀǾàÇ°¾ÈÀüÆò°¡¿øÀº 3D ¹ÙÀÌ¿ÀÇÁ¸°Æà Á¦Ç° °³¹ß¿¡ ÇÊ¿äÇÑ ÁÖ¿ä °í·Á»çÇ×À» ´ãÀº ¡®3D ¹ÙÀÌ¿ÀÇÁ¸°Æà Á¦Ç° µî ¼¼Æ÷-ÁöÁöü º¹ÇÕÁ¦Ç°ÀÇ Æò°¡ °¡À̵å¶óÀΡ¯À» Á¦Á¤¡¤¹ß°£Çß´Ù°í ¹àÇû´Ù.
ÁÖ¿ä ³»¿ëÀº ¡ã3D ¹ÙÀÌ¿ÀÇÁ¸°Æà Á¦Ç° µî ¼¼Æ÷-ÁöÁöü º¹ÇÕÁ¦Ç°ÀÇ ºÐ·ù ±âÁØ ¹× Á¤ÀÇ ¡ãÇ°Áú¡¤Æ¯¼ººÐ¼® ÀÚ·á ¹üÀ§ ¹× °í·Á»çÇ× ¡ãºñÀÓ»ó ¾ÈÀü¼º¡¤À¯È¿¼º Æò°¡½Ã °í·Á»çÇ× ¡ãÀÓ»ó½ÃÇè ½Ã °í·Á»çÇ× µîÀÌ´Ù.
¶ÇÇÑ À¯ÀüÀÚÁ¶ÀÛ ±â¼ú·Î À¯ÀüÀÚÄ¡·áÁ¦¸¦ °³¹ßÇÏ´Â °æ¿ì ÇÊ¿äÇÑ ÁÖ¿ä °í·Á»çÇ×À» ´ãÀº ¡®À¯ÀüÀÚÄ¡·áÁ¦ ºñÀÓ»ó½ÃÇè Æò°¡ °¡À̵å¶óÀΡ¯À» °³Á¤¡¤¹ß°£Çß´Ù.
ÁÖ¿ä °³Á¤ ³»¿ëÀº ¡ãÀ¯ÀüÀÚÄ¡·áÁ¦ °³¹ß ½Ã µ¶¼º¿¡ °üÇÑ ÀÚ·á ¡ãÀ¯ÀüÀÚÄ¡·áÁ¦ °³¹ß ½Ã ¾à¸®ÀÛ¿ë¿¡ °üÇÑ ÀÚ·á µîÀÌ´Ù. |
|
|
¹Î¿øÀξȳ»¼ |
÷´Ü¹ÙÀÌ¿ÀÀǾàÇ° ±ÔÁ¦°úÇÐ »ó´ã »ç·ÊÁý[¹Î¿øÀÎ ¾È³»¼] |
|
¼¼Æ÷Ä¡·áÁ¦ ¹× À¯ÀüÀÚÄ¡·áÁ¦ ½É»ç °ü·Ã ÀÚÁÖ¹¯´Â Áú¹®°ú ´äº¯À» ¸ðÀº »ó´ã»ç·ÊÁý |
|
|
°øÁö/°ø°í |
2017³â ÀǾàÇ°Ç㰡ƯÇ㿬°èÁ¦µµ ¿µÇâÆò°¡ °á°úº¸°í¼ |
|
¾à»ç¹ý Á¦50Á¶ÀÇ11¿¡ µû¶ó ÆǸűÝÁö, ¿ì¼±ÆǸÅÇ°¸ñÇã°¡ µîÀÌ ±¹³» Á¦¾à»ê¾÷, º¸°ÇÁ¤Ã¥, °í¿ëÁõ°¨ µî¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»
ºÐ¼®, Æò°¡ÇÑ º¸°í¼¸¦ ºÙÀÓ°ú °°ÀÌ °ø°³ÇÕ´Ï´Ù.
* (¿¬±¸±â°ü) ¼¿ï´ëÇб³ »êÇÐÇù·Â´Ü(¿¬±¸Ã¥ÀÓÀÚ : ÀÌÅÂÁø ±³¼ö) |
|
|
°øÁö/°ø°í |
WHO ÀÎÇ÷翣ÀÚ ¹é½Å, EÇü °£¿° ¹é½Å, ¹ÙÀÌ¿À½Ã¹Ð·¯ µî¿¡ °üÇÑ °ËÅäÀÇ°ß ¼ö·Å('18.1.18±îÁö) |
|
½ÄÇ°ÀǾàÇ°¾ÈÀüó´Â ¼¼°èº¸°Ç±â±¸(WHO) ¹ÙÀÌ¿ÀÀǾàÇ° Ç¥ÁØÈ ºÐ¾ß Çù·Â¼¾Åͷμ ±¹Á¦ ±âÁØ Á¦,°³Á¤¿¡ °øµ¿À¸·Î Âü¿©ÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í °ü·ÃÇÏ¿© WHO¿¡¼ ¾Æ·¡¿Í °°ÀÌ ÀÎÇ÷翣ÀÚ¹é½Å, EÇü °£¿°¹é½Å ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ °¡À̵å¶óÀÎ(¾È)¿¡ ´ëÇÑ °ËÅäÀÇ°ßÀ» ¼ö·ÅÇÏ°í ÀÖ½À´Ï´Ù.
°¡. ÀÎÇ÷翣ÀÚ ¹é½Å Èĺ¸ ¹ÙÀÌ·¯½ºÀÇ Ç°Áú°ü¸®¿¡ °üÇÑ »ý¹°¾ÈÀü À§ÇèÆò°¡ ¹× °¡À̵å¶óÀÎ
³ª. ÀçÁ¶ÇÕ EÇü °£¿° ¹é½ÅÀÇ Ç°Áú, ¾ÈÁ¤¼º ¹× È¿´É È®ÀÎÀ» À§ÇÑ ±ÇÀå»çÇ×
´Ù. WHO ÁúÀÇ ¹× ÀÀ´äÁý: ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦Ç°
°¢ °¡À̵å¶óÀÎ °¡~´Ù¿¡ ´ëÇÑ °ËÅäÀÇ°ßÀÌ ÀÖ´Â °æ¿ì, 2018.1.18.(¸ñ)±îÁö °¢ ÷ºÎµÈ ÀÇ°ß¾ç½Ä¼¸¦ ÀÛ¼ºÇÏ¿© Çùȸ(johs8739@kobia.kr)·Î Á¦ÃâÇÏ¿© Áֽñ⠹ٶø´Ï´Ù. |
|
|
°ø¹«¿ø
Áöħ¼ |
»ý¹°ÀǾàÇ° ¹× ÇѾà(»ý¾à)Á¦Á¦ À§Çؼº °ü¸®°èȹ ½É»ç ¹× ó¸® ÀýÂ÷(°ø¹«¿ø Áöħ¼) |
|
»ý¹°ÀǾàÇ° ¹× ÇѾà(»ý¾à)Á¦Á¦ À§Çؼº °ü¸®°èȹ ½É»ç ¹× ó¸® ÀýÂ÷(°ø¹«¿ø Áöħ¼) (rev1) |
|
|
°ø¹«¿ø
Áöħ¼ |
¹ÙÀÌ¿À»ý¾à±¹ ¼Ò°ü ÇöÀåÁ¡°Ë Áöħ |
|
¹ÙÀÌ¿ÀÀǾàÇ°, ÇѾà(»ý¾à)Á¦Á¦/ÇѾàÀç, ÈÀåÇ°, ÀǾà¿ÜÇ°, ÀÎüÁ¶Á÷ - (°ø¹«¿ø Áöħ¼) |
|
|
|
|
¡á ±¹³» ¹ÙÀÌ¿ÀÀǾàÇ° ÀÓ»ó½ÃÇè |
|
½ÅûÀÚ |
½ÂÀÎÀÏ |
Á¦Ç°¸í |
½ÃÇè
Á¦¸ñ |
´Ü°è |
Çѱ¹
¿¥¿¡½ºµð(À¯) |
20171218 |
ÀÌÀü¿¡ Ä¡·á¹ÞÀº ÀÌ·ÂÀÌ ¾øÀ¸¸ç Á¾¾ç¿¡¼ PD-L1ÀÌ ¾ç¼º(TPS ¡Ã 50%)ÀÎ Á¦IV±â ÀüÀ̼º ºñ¼Ò¼¼Æ÷ Æó¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î Pembrolizumab + IpilimumabÀ» Pembrolizumab + À§¾à°ú ºñ±³ Æò°¡ÇÏ´Â Á¦3»ó, ¹«ÀÛÀ§¹èÁ¤, ÀÌÁß´«°¡¸² ÀÓ»ó½ÃÇè(KEYNOTE-598) |
3»ó |
MK-3475 |
ÁÖ½Äȸ»ç
¿¡½º¿¤¹ÙÀÌÁ¨ |
20171218 |
½ÅÀåÀÌ½Ä ¼öÇýÀÚ¿¡¼ CMV¿Í BKV ÀçÈ°¼ºÈ ¿¹¹æ DNA ¹é½ÅÀÎ BD03 ±ÙÀ°Åõ¿©ÀÇ ³»¾à¼º°ú ¾ÈÀü¼º Æò°¡¸¦ À§ÇÑ ÀüÇâÀû, °ø°³, ¿ë·®Áõ·®, ´Ù±â°ü, 1»ó ÀÓ»ó½ÃÇè |
1»ó |
BD03 |
|
|
¡á ÇØ¿Ü ÀÓ»ó ÇöȲ |
|
¡à ¹Ì±¹ |
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor
Collaborators |
Phases |
NCT03387098 |
QUILT-3.070: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy |
Pancreatic Cancer |
Drug: Aldoxorubicin HCl|Biological: ALT-803|Biological: ETBX-011|Biological: GI-4000|Biological: haNK for infusion|Biological: avelumab|Biological: bevacizumab
...... |
NantKwest, Inc. |
Phase 1
Phase 2 |
NCT03368729 |
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer |
Metastatic Breast Cancer|HER2 Positive Breast Carcinoma |
Drug: Niraparib|Drug: Trastuzumab |
University of Alabama at Birmingham
Translational Breast Cancer Research Consortium| |
Phase 1
Phase 2 |
NCT03088878 |
A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
B-cell Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Mantle Cell Lymphoma |
Drug: Cirmtuzumab|Drug: Ibrutinib|Drug: Cirmtuzumab plus ibrutinib |
University of California, San Diego
Oncternal Therapeutics, Inc |
Phase 1
Phase 2 |
NCT03368859 |
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab |
Cancer - Metastatic Colorectal |
Drug: ABT-165|Drug: Bevacizumab|Drug: Irinotecan|Drug: Leucovorin|Drug: Fluorouracil - bolus|Drug: Fluorouracil - infusion |
AbbVie |
Phase 2 |
NCT03367715 |
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma |
MGMT-unmethylated Glioblastoma (GBM)|GBM |
Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy (RT) |
New York University School of Medicine |
Phase 2 |
NCT03272633 |
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia in Remission|Hematopoietic Cell Transplantation Recipient|JAK2 Gene Mutation|Loss of Chromosome 17p|Mantle Cell Lymphoma|Minimal Residual Disease..... |
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Biological: Irradiated Allogeneic Cells... |
Rutgers, The State University of New Jersey|National Cancer Institute (NCI) |
Phase 2 |
NCT03358706 |
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease |
Crohn Disease |
Drug: Ustekinumab IV Infusion|Drug: Ustekinumab SC Injection|Drug: Midazolam 2 mg|Drug: Warfarin 10 mg|Drug: Vitamin K 10 mg|Drug: Omeprazole 20 mg|Drug: Dextromethorphan 30 mg|Drug: Caffeine 100 mg |
Janssen Research & Development, LLC |
Phase 1 |
|
|
|
¡à À¯·´ |
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
ºñ°í |
NCT03295383 |
Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid |
Severe Forms of Mucous Membrane Pemphigoid |
Drug: Rituximab 1g IV|Drug: Cyclophosphamide 50Mg Oral Tablet|Drug: Placebo of Rituximab|Drug: Placebo Oral Tablet |
University Hospital, Rouen |
Phase 3 |
ÇÁ¶û½º |
NCT03387046 |
A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS) |
Multiple Sclerosis, Relapsing-Remitting |
Dietary Supplement: D-aspartate
Drug: Placebo
Biological: IFN beta-1a
Drug: Methylprednisolone |
Merck KGaA |
Phase 2 |
µ¶ÀÏ |
NCT03358706 |
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease |
Crohn Disease |
Drug: Ustekinumab IV Infusion|Drug: Ustekinumab SC Injection|Drug: Midazolam 2 mg|Drug: Warfarin 10 mg|Drug: Vitamin K 10 mg|Drug: Omeprazole 20 mg|Drug: Dextromethorphan 30 mg|Drug: Caffeine 100 mg |
Janssen Research & Development, LLC |
Phase 1 |
µ¶ÀÏ |
|
|
|
¡à Áß±¹ |
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03380689 |
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer |
Metastatic Colorectal Cancer |
Drug: S-1|Drug: Irinotecan|Drug: Bevacizumab |
Fujian Cancer Hospital |
Phase 1 |
|
|
|
¡á Çùȸ ¼Ò½Ä |
|
|
|
¡á Çùȸ ¼Ò½Ä : ȸ¿ø»ç ´ë»ó '17³â 12¿ù ¹ß°£ ÀÚ·á ¾È³» |
|
|
Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ¿¡¼´Â ¡¸2017 ¹ÙÀÌ¿ÀITÇ÷§Æû¡¹ »ç¾÷ÀÇ ÀÏȯÀ¸·Î
±¹³» ¹ÙÀÌ¿ÀÀǾàÇ°ÀÇ ÇØ¿Ü ÁøÃâÀ» Áö¿øÇϱâ À§ÇØ
ÃÑ 15±¹¿¡ ´ëÇÑ ±Û·Î¹ú ÁøÃâ Àü·« Á¤º¸ ÀÚ·áÁýÀ» ¸¶·ÃÇÏ¿´½À´Ï´Ù.
(¹Ì±¹/À¯·´/ÀϺ»/Áß±¹/Àεµ/ºê¶óÁú/¸ß½ÃÄÚ/ÅÍÅ°/ű¹/È£ÁÖ/·¯½Ã¾Æ
/»ç¿ìµð¾Æ¶óºñ¾Æ/º£Æ®³²/Àεµ³×½Ã¾Æ/ÆÄÅ°½ºÅº)
º» º¸°í¼¿¡´Â °¢±¹ ±ÔÁ¦±â°ü Á¤º¸, ÀÎÇã°¡ ü°è(¡ãÀÓ»ó½ÃÇè, ¡ãÇ°¸ñÇã°¡, ¡ãGMP), »ê¾÷Á¤º¸ µîÀÌ ¼ö·ÏµÇ¾î ÀÖ½À´Ï´Ù. |
Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ¿¡¼´Â ¹ÙÀÌ¿ÀÀǾàÇ° »ê¾÷°è ¼ºÀå ±âÃÊ ÀڷḦ
Á¦°øÇÏ°íÀÚ '¹ÙÀÌ¿ÀÀǾàÇ° »ê¾÷µ¿Çâ º¸°í¼'¸¦ ¸¶·ÃÇÏ¿´½À´Ï´Ù.
º» º¸°í¼¿¡´Â ±¹³»¿Ü ¹ÙÀÌ¿ÀÀǾàÇ° ½ÃÀå ÇöȲÀÌ ¼ö·ÏµÇ¾î ÀÖ½À´Ï´Ù.
»ó¼¼ ³»¿ë: ȨÆäÀÌÁö>ÀÚ·á½Ç>Çùȸ°£Ç๰ pdf Âü°í
|
Çùȸ°£Ç๰ °Ô½ÃÆÇ ¹Ù·Î°¡±â [Click] |
»ê¾÷µ¿Çâ º¸°í¼ È®ÀÎÇϱâ[Click] |
º¸°í¼ ¿¶÷ ¼ºñ½º´Â Çùȸ ȸ¿ø»ç ¼Ò¼Ó ȸ¿øÀ¸·Î Á¦Çѵ˴ϴÙ. Çùȸ ȸ¿ø»ç °¡ÀÔ ÀýÂ÷ È®ÀÎÇϱâ (Click) |
|
|
|
|
|
´º½º·¹ÅÍ ±¸µ¶ ½Åû: info@kobia.kr (¹«·á)
(06725) ¼¿ï½Ã ¼Ãʱ¸ ³²ºÎ¼øȯ·Î 333±æ 10, ¿øÀÏBD 4F
COPYRIGHT(C). Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ, All Rights Reserved.
|
|
|
|